Cargando…
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention
Antiplatelet agents are a cornerstone in the treatment of acute arterial thrombotic events and in the prevention of thrombus formation. However, existing antiplatelet agents (mainly aspirin, the combination of aspirin and dipyridamole and clopidogrel) reduce the risk of vascular events only by about...
Autores principales: | Weber, Ralph, Diener, Hans-Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823155/ https://www.ncbi.nlm.nih.gov/pubmed/20738445 http://dx.doi.org/10.1111/j.1582-4934.2010.01162.x |
Ejemplares similares
-
Antiplatelet therapy in secondary stroke prevention – state of the art
por: Diener, Hans-Christoph, et al.
Publicado: (2010) -
Oral anticoagulation versus antiplatelet therapy for
secondary stroke prevention in patients with embolic stroke of
undetermined source: A systematic review and
meta-analysis
por: Hariharan, Nikhil Nair, et al.
Publicado: (2022) -
Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention
por: Srivastava, Padma
Publicado: (2010) -
Antiplatelets in Secondary Stroke Prevention
por: Shulga, Olga, et al.
Publicado: (2011) -
Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies
por: Frere, Corinne, et al.
Publicado: (2019)